SCHEMBL9722176

SCHEMBL9722176

CCCCC/C=C\C/C=C\CCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O

nearest known ligand 0.82

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSPD1 P10809 1/20 0.82
HSPE1 P61604 1/20 0.82
TST Q16762 1/20 0.82
MAPT P10636 1/20 0.82
RECQL P46063 1/20 0.82
BLM P54132 1/20 0.82
TDP1 Q9NUW8 1/20 0.82
FAAH O00519 2/20 0.52
DGKA P23743 1/20 0.51
LPAR1 Q92633 6/20 0.49
LPAR4 Q99677 3/20 0.49
LPAR2 Q9HBW0 3/20 0.49
LPAR3 Q9UBY5 3/20 0.49
ENPP2 Q13822 2/20 0.49
LPAR5 Q9H1C0 2/20 0.49
CES2 O00748 1/20 0.49
LPAR6 P43657 1/20 0.49
TRPV1 Q8NER1 1/20 0.49
SELP P16109 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8163824 1.00 HSPD1 (0.82) HSPD1HSPE1TSTMAPTRECQL
Ascorbyl Gamolenate SCHEMBL3142843 0.99 HSPD1 (0.80) HSPD1HSPE1TSTMAPTRECQL
SCHEMBL2241479 0.97 MAPT (0.76) HSPD1HSPE1TSTMAPTRECQL
SCHEMBL14880173 0.97 HSPD1 (0.87) HSPD1HSPE1TSTMAPTRECQL
SCHEMBL9722188 0.91 HSPD1 (0.67) HSPD1HSPE1TSTMAPTRECQL
SCHEMBL24511445 0.90 MAPT (1.00) HSPD1HSPE1TSTMAPTRECQL
SCHEMBL22749133 0.90 MAPT (1.00) HSPD1HSPE1TSTMAPTRECQL
SCHEMBL22749131 0.90 MAPT (1.00) HSPD1HSPE1TSTMAPTRECQL
SCHEMBL22749146 0.90 MAPT (1.00) HSPD1HSPE1TSTMAPTRECQL
SCHEMBL1762372 0.90 MAPT (1.00) HSPD1HSPE1TSTMAPTRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5078989-A Linoleic Acid-Vitamin C Esters SUNSTAR K.K. (JP) 1992-01-07 US claimed
WO-2024129968-A1 INJECTABLE COMPOSITIONS FOR TREATING JOINT CONDITIONS OHIO STATE INNOVATION FOUNDATION (US) 2024-06-20 WO disclosed
US-20220118159-A1 ANTIOXIDANT-RELEASING VITREOUS SUBSTITUTES AND USES THEREOF OHIO STATE INNOVATION FOUNDATION 2022-04-21 US disclosed
EP-3920986-A1 ANTIOXIDANT-RELEASING VITREOUS SUBSTITUTES AND USES THEREOF Ohio State Innovation Foundation (US) 2021-12-15 EP disclosed
CN-113646014-A Antioxidant-releasing vitreous substitute and use thereof 俄亥俄州创新基金会 2021-11-12 CN disclosed
WO-2020163872-A1 ANTIOXIDANT-RELEASING VITREOUS SUBSTITUTES AND USES THEREOF OHIO STATE INNOVATION FOUNDATION (US) 2020-08-13 WO disclosed
US-9295630-B2 Vitamin C complexes CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2016-03-29 US disclosed
US-9289428-B2 Conveniently injectable or implantable sustained-release antioxidant formulations for therapies of ocular maladies or cancer RAMSCOR, INC. (US) 2016-03-22 US disclosed
US-20150045426-A1 VITAMIN C COMPLEXES Universite Paris-Saclay (FR) 2015-02-12 US disclosed
US-20140329785-A1 Conveniently Injectable or Implantable Sustained-Release Antioxidant Formulations for Therapies of Ocular Maladies or Cancer RAMSCOR, INC. (US) 2014-11-06 US disclosed
EP-2717866-A2 CONVENIENTLY INJECTABLE OR IMPLANTABLE SUSTAINED-RELEASE ANTIOXIDANT FORMULATIONS FOR THERAPIES OF OCULAR MALADIES OR CANCER Ramscor, Inc. (US) 2014-04-16 EP disclosed
WO-2013058838-A2 CONVENIENTLY INJECTABLE OR IMPLANTABLE SUSTAINED-RELEASE ANTIOXIDANT FORMULATIONS FOR THERAPIES OF OCULAR MALADIES OR CANCER WONG VERNON G (US) 2013-04-25 WO disclosed
US-5078989-A Linoleic Acid-Vitamin C Esters SUNSTAR K.K. (JP) 1992-01-07 US disclosed
EP-0296483-A2 Preparation of ascorbic acid 6-esters F. HOFFMANN-LA ROCHE AG (CH) 1988-12-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150045426-A1 VITAMIN C COMPLEXES PROC, CYP27B1, CYP24A1 HSPD1 507/4885HSPE1 364/4885TST 2584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.